What is the official ID of this bill?

The official print number for this legislation is HR 1620.

When did the legislative process begin?

The process officially started on 2025-02-26.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/119/bills/hr1620/BILLS-119hr1620ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

Who is the primary sponsor?

The primary sponsor is Rep. Matsui, Doris O. [D-CA-7].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Introduced in House

Analysis and Potential Impact of HR 1620

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Easier Access to Cancer Genetic Testing for Patients

Q: What are the main provisions?

Key points include: Medicare, Medicaid, and CHIP will cover advanced genetic and laboratory tests (like DNA sequencing) for cancer patients. These tests will be covered upon diagnosis, recurrence, and for treatment planning or monitoring cancer progression. The act includes an education program for physicians and the public on genomic testing and the role of genetic counselors.

This act aims to facilitate access to advanced genetic and laboratory tests for individuals diagnosed with cancer. It means Medicare, Medicaid, and CHIP will cover the costs of these tests, which can help in better treatment planning and disease monitoring, reducing financial burden for patients.

Key points

Medicare, Medicaid, and CHIP will cover advanced genetic and laboratory tests (like DNA sequencing) for cancer patients.

These tests will be covered upon diagnosis, recurrence, and for treatment planning or monitoring cancer progression.

The act includes an education program for physicians and the public on genomic testing and the role of genetic counselors.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Introduced

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Finn Sawyer Access to Cancer Testing Act

Print number: HR 1620

Sponsor: Rep. Matsui, Doris O. [D-CA-7]

Process start date: 2025-02-26

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash

Source data: api.congress.gov

AI work logs for this document launch